Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
- Symbol
- PCVX
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $8.55B
- 52 week range
- 31.89 - 65
Valuation
- Share price
- $56.49 (close of 2026-09-23)
- P/E (TTM)
- -7.73x
- Price to book
- 3.10x
- Price to free cash flow
- -9.56x
- Enterprise value
- $7.17B
- Book value per share
- $19.05
Price performance
| Period | Change |
|---|
| 1 day | -4.12% |
| 5 days | -4.59% |
| 1 month | -9.79% |
| 3 months | +8.72% |
| 6 months | +0.98% |
| Year to date | +22.43% |
| 1 year | +70.41% |
| 3 years | +7.70% |
| 5 years | +115.78% |
| All time | +116.02% |
Profitability and growth
- Return on equity
- -28.55%
- Return on invested capital
- -74.37%
- Return on assets
- -25.53%
- Return on capital employed
- -33.02%
- Net income growth
- -65.25%
- Free cash flow growth
- -40.89%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -10.46%
- Current ratio
- 5.72x
- Net debt to EBITDA
- 1.20x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- EBITDA
- $-907.27M
- Net income
- $-766.63M
- Earnings per share
- $-5.63
- Research and development
- $794.31M
- Shares outstanding
- 136.09M
Income statement by year
| Period end | Net income | EPS |
|---|
| 2025-12-31 | $-766.63M | $-5.63 |
| 2024-12-31 | $-463.93M | $-3.80 |
| 2023-12-31 | $-402.27M | $-4.14 |
| 2022-12-31 | $-223.49M | $-3.44 |
| 2021-12-31 | $-100.08M | $-1.93 |
| 2020-12-31 | $-89.22M | $-3.02 |
| 2019-12-31 | $-50.27M | $-13.25 |
| 2018-12-31 | $-29.48M | $-8.12 |
Margins and returns by year
| Period end | Return on equity | Return on capital |
|---|
| 2025-12-31 | -28.55% | -74.37% |
| 2024-12-31 | -14.03% | -34.95% |
| 2023-12-31 | -32.43% | -247.03% |
| 2022-12-31 | -23.44% | -578.07% |
| 2021-12-31 | -35.24% | -189.07% |
| 2020-12-31 | -25.80% | - |
| 2019-12-31 | 47.26% | - |
| 2018-12-31 | 51.08% | - |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $1.56B |
| 2024-12-31 | $1.75B |
| 2023-12-31 | $1.08B |
| 2022-12-31 | $931.38M |
| 2021-12-31 | $245.97M |
| 2020-12-31 | $386.20M |
| 2019-12-31 | $58.98M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-669.29M | $138.84M |
| 2024-12-31 | $-475.05M | $84.82M |
| 2023-12-31 | $-312.85M | $48.76M |
| 2022-12-31 | $-176.44M | $23.65M |
| 2021-12-31 | $-127.95M | $10.73M |
| 2020-12-31 | $-47.78M | $5.43M |
| 2019-12-31 | $-48.34M | $1.19M |
| 2018-12-31 | $-32.24M | $749.00K |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-03
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | - |
| 2026-05-06 | - | - |
| 2026-02-24 | - | - |
| 2025-11-04 | - | - |
| 2025-08-06 | - | - |
| 2025-05-07 | - | - |
| 2025-02-25 | - | - |
| 2024-11-05 | - | - |
Filings and sources
- Company website
- vaxcyte.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades